Among the biggest risers on the S&P 500 on Monday January 25 was Johnson & Johnson ($JNJ), popping some 1.49% to a price of $165.98 a share with
some 9.73 million shares trading hands.
Starting the day trading at $165.01, Johnson & Johnson reached an intraday high of $166.09 and hit intraday lows of $163.66. Shares gained $2.43 apiece by day’s end. Over the last 90
days, the stock’s average daily volume has been n/a of its 2.63 billion share total float. Today’s action puts the stock’s 50-day SMA at $n/a and 200-day
SMA at $n/a with a 52-week range of $109.17 to $165.16.
Johnson & Johnson is the world’s largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson has its corporate headquarters located in New Brunswick, NJ and employs 132,200 people. Its market cap has now risen to $436.95 billion after today’s trading, its P/E
ratio is now n/a, its P/S n/a, P/B 6.78, and P/FCF n/a.
You can find a complete fundamental analysis of this stock at our For a complete fundamental analysis analysis of Johnson & Johnson, check out Stock Valuation Analysis tool for JNJ.
Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start
The Dow Jones Industrial Average (DJIA) is the most visible stock index in the United States, but that doesn’t make it the best. In fact, the industry standard for market watchers and institutional
investors in gauging portfolio performance is the S&P 500.
The DJIA relies on just 30 stocks as a sample of large- and mega-cap firms, dwarfed by the 500 contained in the S&P 500, and it also weights its returns using an outdated and flawed price-weighting
method. The S&P 500’s weighting is based on market cap, making it a much better representation of actual market performance for large- and mega-cap stocks.
To get more information on Johnson & Johnson and to follow the company’s latest updates, you can visit the company’s profile page here:
JNJ’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s
Newsdesk. Also, don’t forget to sign-up for our daily
email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer